Clinical Trials Pipeline & In-Development

KN056

also known as: KN-056

Alphamab's GLP-1 / glucagon dual agonist — an early-clinical Chinese entry in the GLP-1/glucagon mechanism space pioneered by cotadutide and now represented by pemvidutide and survodutide.

A dual GLP-1 / glucagon receptor agonist peptide developed by Alphamab (Suzhou), in early clinical development in China for obesity and MASH; occupies the same mechanism space as pemvidutide, survodutide, and the discontinued cotadutide.

Mechanism of action

Balanced agonism at GLP-1 and glucagon receptors — same mechanism class as cotadutide, pemvidutide, and survodutide. The glucagon arm adds thermogenesis / hepatic fat oxidation to standard GLP-1 incretin effects.

Primary uses

Obesity (early clinical)
MASH (early clinical)

Typical dosing

once weekly (subcutaneous)

Early-clinical doses not publicly finalized.

Regulatory status

Not approved. Early clinical development in China.

References

[manufacturer] Alphamab pipeline disclosures — KN056 GLP-1/glucagon dual agonist.

Related peptides

Cotadutide

AstraZeneca's discontinued GLP-1/glucagon dual agonist — shelved in 2023 despite positive Phase 2 data in NASH and obesity, reportedly for commercial rather than safety reasons. Included for pipeline completeness; the mechanism lives on in pemvidutide, survodutide, and the glucagon arm of retatrutide.

Pemvidutide

Altimmune's GLP-1 / glucagon co-agonist — received FDA Breakthrough Therapy Designation for MASH in January 2026 after positive IMPACT Phase 2b antifibrotic data, with Phase 3 initiation planned for 2026.

Survodutide

A once-weekly GLP-1/glucagon co-agonist in late-stage trials for obesity, type 2 diabetes, and MASH.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.